<DOC>
	<DOCNO>NCT00776763</DOCNO>
	<brief_summary>Aims trial : Establishing profile growth factor mediators angiogenesis different ocular fluid ( aqueous humour , vitreous gel ocular liquid vitrectomized eye ) , 2 frequent proliferative retinopathy - diabetic proliferative retinopathy ( PDR ) exudative age relate macular degeneration ( AMD ) . Following dynamic profile intravitreal administration Bevacizumab ( Avastin ) anti-VEGF blocker . Materials : The research conduct follow category patient group : - nondiabetic patient without AMD diagnose proliferative ocular disease ( control ) - patient age relate macular degeneration ( AMD group ) intravitreal injection Avastin - diabetic patient different type diabetic retinopathy , intravitreal Avastin ( diabetic group ) Methods : Samples different ocular fluid collect group patient . 10 growth factor 10 cytokine determine ocular fluid sample . Results : The result biochemical measurement statistically interpret order obtain conclusion clinical practice . Conclusions : The conclusion trial use exclusively research publication communication , well clinical practice .</brief_summary>
	<brief_title>Ocular Growth Factors Profile Proliferative Retinopathies Before After Intravitreal Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>age 20 year nondiabetic patient require cataract surgery vitrectomy different posterior segment nonproliferative disorder control group diabetic patient ask ophthalmologic treatment different degree decrease visual acuity diabetic group diabetic patient require cataract surgery vitrectomy diabetic group age relate macular degeneration patient ask ophthalmologic treatment different degree decrease visual acuity age relate macular degeneration group age relate macular degeneration patient require cataract surgery vitrectomy age relate macular degeneration group patient age 20 year patient accept sign informed consent trial patient receive antiVEGF therapy proliferative inflammatory ocular disease patient receive type intraocular injection pharmaceutical agent patient clinical type malignancy pathologic antecedent patient recent penetrate trauma ( less 1 year old ) patient operate different ocular disorder require combination antimetabolite ( ex . 5FU Mitomycin C trabeculectomy ) patient intraocular inflammation infection pathology contraindicate open globe surgery intraocular injection antiVEGF blocker</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>